AACR 2023 | Improving outcomes for patients who relapse after alloSCT & evaluating CD19 CARs against EMD in ALL
Rebecca Epperly, MD, St. Jude Children’s Research Hospital, Memphis, TN, summarizes research presented at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. First, Dr Epperly discusses the importance of getting patients who relapse after allogeneic stem cell transplantation (alloSCT) into remission before a secondary transplant. Following this, Dr Epperly shares some insights into a study evaluating CD19 CAR-T cells against extramedullary disease (EMD) in acute lymphoblastic leukemia (ALL), and highlights the value of translating this knowledge into the solid tumor space. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
